Good_老虎社区_美港股上老虎

Leehui1984
2021-07-30

Good

Gilead: Q2 Earnings Snapshot<blockquote>吉利德：第二季度收益快照</blockquote>

FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net incom

Gilead: Q2 Earnings Snapshot<blockquote>吉利德：第二季度收益快照</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":808726927,"tweetId":"808726927","gmtCreate":1627611578769,"gmtModify":1633757777913,"author":{"id":4089182849487330,"idStr":"4089182849487330","authorId":4089182849487330,"authorIdStr":"4089182849487330","name":"Leehui1984","avatar":"https://static.tigerbbs.com/38381321356ff7f33e4c88f960c1a24c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good</p></body></html>","htmlText":"<html><head></head><body><p>Good</p></body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/808726927","repostId":1165365936,"repostType":4,"repost":{"id":"1165365936","kind":"news","pubTimestamp":1627607851,"share":"https://www.laohu8.com/m/news/1165365936?lang=zh_CN&edition=full","pubTime":"2021-07-30 09:17","market":"us","language":"en","title":"Gilead: Q2 Earnings Snapshot<blockquote>吉利德：第二季度收益快照</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1165365936","media":"sfgate","summary":"FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net incom","content":"<p>FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.</p><p><blockquote>加利福尼亚州福斯特市。（美联社）_吉利德科学公司（GILD）周四公布第二季度净利润为15.2亿美元，此前去年同期出现亏损。</blockquote></p><p> On a per-share basis, the Foster City, California-based company said it had net income of $1.21. Earnings, adjusted for non-recurring costs, were $1.87 per share.</p><p><blockquote>这家总部位于加利福尼亚州福斯特市的公司表示，按每股计算，其净利润为1.21美元。经非经常性成本调整后，每股收益为1.87美元。</blockquote></p><p> The results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.76 per share.</p><p><blockquote>结果超出了华尔街的预期。Zacks Investment Research调查的九位分析师的平均预期为每股收益1.76美元。</blockquote></p><p> The HIV and hepatitis C drugmaker posted revenue of $6.22 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $6.15 billion.</p><p><blockquote>这家艾滋病毒和丙型肝炎制药商公布的同期收入为62.2亿美元，也超出了华尔街的预测。Zacks调查的六位分析师预计为61.5亿美元。</blockquote></p><p> Gilead expects full-year earnings in the range of $6.90 to $7.25 per share.</p><p><blockquote>吉利德预计全年每股收益在6.90美元至7.25美元之间。</blockquote></p><p> Gilead shares have climbed 20% since the beginning of the year, while the S&amp;P's 500 index has increased 18%. In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.</p><p><blockquote>自今年年初以来，吉利德股价已上涨20%，而标准普尔500指数则上涨18%。在周四交易的最后几分钟，股价触及69.81美元，过去12个月跌幅略高于4%。</blockquote></p><p></p>","source":"lsy1627607889170","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead: Q2 Earnings Snapshot<blockquote>吉利德：第二季度收益快照</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead: Q2 Earnings Snapshot<blockquote>吉利德：第二季度收益快照</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">sfgate</strong><span class=\"h-time small\">2021-07-30 09:17</span>\n</p>\n</h4>\n</header>\n<article>\n<p>FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.</p><p><blockquote>加利福尼亚州福斯特市。（美联社）_吉利德科学公司（GILD）周四公布第二季度净利润为15.2亿美元，此前去年同期出现亏损。</blockquote></p><p> On a per-share basis, the Foster City, California-based company said it had net income of $1.21. Earnings, adjusted for non-recurring costs, were $1.87 per share.</p><p><blockquote>这家总部位于加利福尼亚州福斯特市的公司表示，按每股计算，其净利润为1.21美元。经非经常性成本调整后，每股收益为1.87美元。</blockquote></p><p> The results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.76 per share.</p><p><blockquote>结果超出了华尔街的预期。Zacks Investment Research调查的九位分析师的平均预期为每股收益1.76美元。</blockquote></p><p> The HIV and hepatitis C drugmaker posted revenue of $6.22 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $6.15 billion.</p><p><blockquote>这家艾滋病毒和丙型肝炎制药商公布的同期收入为62.2亿美元，也超出了华尔街的预测。Zacks调查的六位分析师预计为61.5亿美元。</blockquote></p><p> Gilead expects full-year earnings in the range of $6.90 to $7.25 per share.</p><p><blockquote>吉利德预计全年每股收益在6.90美元至7.25美元之间。</blockquote></p><p> Gilead shares have climbed 20% since the beginning of the year, while the S&amp;P's 500 index has increased 18%. In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.</p><p><blockquote>自今年年初以来，吉利德股价已上涨20%，而标准普尔500指数则上涨18%。在周四交易的最后几分钟，股价触及69.81美元，过去12个月跌幅略高于4%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php\">sfgate</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165365936","content_text":"FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.\nOn a per-share basis, the Foster City, California-based company said it had net income of $1.21. Earnings, adjusted for non-recurring costs, were $1.87 per share.\nThe results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.76 per share.\nThe HIV and hepatitis C drugmaker posted revenue of $6.22 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $6.15 billion.\nGilead expects full-year earnings in the range of $6.90 to $7.25 per share.\nGilead shares have climbed 20% since the beginning of the year, while the S&P's 500 index has increased 18%. In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.","news_type":1,"symbols_score_info":{"GILD":0.9}},"isVote":1,"tweetType":1,"viewCount":1458,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}